BiotechTube
Saverna Therapeutics

Saverna Therapeutics

Basel, Switzerland· Est.
saverna.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $11M

Overview

Saverna Therapeutics is a private, preclinical-stage biotech leveraging a unique AI- and NMR-driven platform to discover small molecule drugs targeting the largely unexplored non-coding RNA space, particularly microRNAs. Founded by a team of ex-Novartis scientists, the company aims to partner with larger pharmaceutical firms for discovery and early-stage development. To date, it has been financed through self-funding and public grants from Swiss and European innovation programs.

InflammationAutoimmune DiseasesCancerInfection

Technology Platform

Proprietary drug discovery platform combining fragment-based screening using Nuclear Magnetic Resonance (NMR) spectroscopy with Artificial Intelligence/Machine Learning for hit identification and optimization, specifically designed to target non-coding RNA structures like microRNAs.

Funding History

1
Total raised:$11M
Seed$11M

Opportunities

The vast, underexplored target space of non-coding RNA (e.g., microRNAs) offers potential for first-in-class therapies in areas of high unmet need.
The company's integrated AI/NMR platform could significantly improve the efficiency and success rate of RNA drug discovery, creating value both through internal programs and lucrative partnerships with large pharmaceutical companies.

Risk Factors

The scientific challenge of developing selective, orally bioavailable small molecules against RNA targets is significant and unproven at scale for miRNAs.
As a pre-revenue company dependent on grants, securing substantial venture funding or a partnership is critical for survival and progression.
Competition in the RNA-targeted small molecule field is intensifying rapidly.

Competitive Landscape

Saverna operates in the emerging and competitive field of RNA-targeting small molecules, competing with well-funded biotechs like Arrakis Therapeutics, Skyhawk Therapeutics, and Remix Therapeutics, as well as internal efforts at large pharmaceutical companies. Differentiation relies on its specific NMR/AI platform focus on pre-miRNA structures and its experienced, ex-Novartis team.

More companies in Switzerland →